Xencor

The proprietary DN mechanism can be applied to all proteins that are structurally related to TNF, collectively referred to as the TNF superfamily. Proteins in this class include 4-1BBL, APRIL, BAFF, CD27L, CD30L, CD40L, FasL, LIGHT, OX40L, RANKL, TNFα, TNFß, TNFc, TRAIL, TWEAK, and VEGI. TNF superfamily members are a rich class of drug targets that have been implicated in a broad range of pathophysiologies, including lupus and other autoimmune diseases, osteoporosis, inflammation, and cancer. In addition to DN-TNF, Xencor is actively pursuing inhibitors of other members of this family such as RANKL for the treatment of metastatic bone disease and osteoporosis, and BLyS/BAFF for lupus and other autoimmune diseases.